Dr Anastasiou is a medical doctor specializing in both Internal Medicine and Hematology. Her focus of interest is on acute leukemia and stem cell transplantation. During her post-doctoral fellowship, she has extensively studied changes in phenotype of blastic cells in patients with acute myeloid leukemia under FLT3 tyrosine kinase inhibitors. Having worked in a center of reference for stem cell transplantation and cell therapy, she has gained profound knowledge in chimeric antigen receptor (CAR) T-cell therapy. Her thesis is on microangiopathic complications after T-cell depleted hematopoietic stem cell transplantation. She has extensive experience of more than 10 years in phase II/III clinical trial involving patients with lymphoid and myeloid malignancies. Dr Anastasiou has authored and co-authored scientific articles in journals including Blood, Transplant Cell Therapy, and the British Journal of Medicine. She has presented abstracts at several international conferences. She has won the Young Investigator’s Award for a presentation on Acute Myeloid Leukemia, Swiss Group for Clinical Cancer Research (SAKK). Dr Anastasiou has edited manuscripts for both students and colleagues at her institution. She has worked as Medical Data Reviewer since 2022. Her duties in this role include protocol review, adherence to protocol activities, data validation planning, and clinical database specification review for clinical studies. She joined Edanz as a research consultant in 2023. Dr Anastasiou has worked as Medical Advisor for the pharmaceutical industry and she has contributed to the composition of research protocols, investigator brochures (IB), clinical study reports (CSR), and requests for proposal (RFP).